FUKUOKA RA study for joint preserving effects with ACTEMRA

FUKUOKA RA study for joint preserving effects with ACTEMRA - F-ACT Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014109

Enrollment

110

Registered

2014-05-29

Start date

2014-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patient who is diagnosed as rheumatoid arthritis according to ACR/EULAR new classification criteria in 2010. 2. The patient who is in the treatment of more than 1 kind of former DMARDs. 3. The patient who has Disease activity score 28 (DAS28-ESR)>=3.2 4. The patient who has never used tocilizumab before. 5. The patients whose attending doctor diagnoses that the treatment of biomedicine is valid according to the guideline of biomedicine use for RA of Japan College of Rheumatology. 6. The patient who wants TCZ-SC treatment. 7. The patient who gave his/her written consent to participation in this research.

Exclusion criteria

Exclusion criteria: 1. If the medicine in this research is contraindicated for the patient. 2. When the research PI or physician-in-charge diagnoses the patient is unsuitable for the research.

Design outcomes

Primary

Measure	Time frame
Amount of change of joint preserving effects (Yearly progression) as at 52 weeks by vdH-modified Total Sharp Score from before the administration.	—

Countries

Japan

Contacts

Public ContactMasakazu Kondo

Fukuoka RA Biologics Registry office

kondo-clinic@clinicalsupport.co.jp092-762-2280

Outcome results